Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462340 · ClinicalTrials.gov registry record · Phase 1
PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT05462340 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 117 participants.
The verdict
NCT05462340, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.
Interventions
- DRUG [18F]ASEM
- DRUG [18F]AZAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2022-08-18 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462340
The ClinicalTrials.gov registry entry for NCT05462340 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [18F]ASEM is the first listed.
NCT05462340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05462340 about?
NCT05462340 is a clinical study titled "PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia". The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to...
What is the current status of trial NCT05462340?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2022-08-18. Estimated completion is 2025-01-07.
What interventions are being tested in trial NCT05462340?
The interventions under investigation include: [18F]ASEM (DRUG), [18F]AZAN (DRUG).
Who is sponsoring clinical trial NCT05462340?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.